Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

50.88 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 419,077
Open 50.88
Bid (Size) 51.51 (300)
Ask (Size) 51.53 (200)
Prev. Close 50.88
Today's Range 50.88 - 50.88
52wk Range 43.08 - 93.80
Shares Outstanding N/A
Dividend Yield 4.32%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has... 
Via PredictStreet
Topics Economy Lawsuit World Trade

Performance

YTD
N/A
N/A
1 Month
+7.3%
+7.3%
3 Month
-13.4%
-13.4%
6 Month
-26.4%
-26.4%
1 Year
-41.9%
-41.9%

More News

Read More
News headline image
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026 ↗
Via MarketBeat
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Why Novo Nordisk Stock Dropped on Monday ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
The 2026 Horizon: Wall Street Bets on the 'Application Era' and the Nuclear Renaissance
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
Market Breather: Benchmarks Pause Record-Breaking Year as Volatility Signals Year-End Reset
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
This Beaten-Down Stock Just Jumped By 8%. Time to Buy? ↗
Via The Motley Fool
News headline image
Novo Nordisk Slashes Weight Loss Drug Price By Up To 50% In China: Report ↗
Via Stocktwits
Topics Intellectual Property
News headline image
The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. ↗
Via The Motley Fool
News headline image
3 Drug Stocks to Buy at a Discount ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Invest in Ozempic Maker Novo Nordisk in 2026? ↗
Via The Motley Fool
News headline image
Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026 ↗
Via MarketBeat
News headline image
This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling ↗
Via Stocktwits
News headline image
Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree ↗
Via The Motley Fool
News headline image
Betting on the 'Santa Squeeze': Unusual Options Activity Surges as 2025 Draws to a Close
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle? ↗
Via The Motley Fool
News headline image
Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill
Via PredictStreet
Topics Economy Intellectual Property World Trade
News headline image
The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
Via PredictStreet
Topics Economy Government Intellectual Property
News headline image
The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era
Via PredictStreet
Topics Economy

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 50.88
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 12/31/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.